Guyasuta Investment Advisors Inc. lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 149,171 shares of the medical instruments supplier’s stock after selling 1,492 shares during the quarter. Becton, Dickinson and makes up 3.5% of Guyasuta Investment Advisors Inc.’s holdings, making the stock its 2nd biggest position. Guyasuta Investment Advisors Inc. owned about 0.07% of Becton, Dickinson and worth $29,105,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. acquired a new position in Becton, Dickinson and during the first quarter worth $105,000. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares during the last quarter. QCI Asset Management Inc. NY lifted its stake in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after acquiring an additional 60 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares during the last quarter. Finally, Financial Architects Inc lifted its stake in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares during the last quarter. 87.12% of the stock is owned by institutional investors.

Several research firms have recently weighed in on BDX. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their target price for the company from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Cowen and Company reiterated a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Wells Fargo & Company began coverage on Becton, Dickinson and in a report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target for the company. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $200.93.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last ninety days. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company (NYSE:BDX) opened at 193.73 on Wednesday. The firm has a 50-day moving average price of $197.55 and a 200-day moving average price of $192.30. The firm has a market capitalization of $44.09 billion, a price-to-earnings ratio of 56.10 and a beta of 1.05. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the previous year, the company earned $2.35 earnings per share. The company’s quarterly revenue was down 5.1% on a year-over-year basis. Analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a dividend of $0.73 per share. The ex-dividend date was Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.51%. Becton, Dickinson and’s payout ratio is currently 83.43%.

TRADEMARK VIOLATION NOTICE: “Guyasuta Investment Advisors Inc. Has $29.11 Million Stake in Becton, Dickinson and Company (BDX)” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/guyasuta-investment-advisors-inc-has-29-11-million-stake-in-becton-dickinson-and-company-bdx/1606810.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.